The stock of X4 Pharmaceuticals Inc (NASDAQ:XFOR) last traded at $0.75, down -6.13% from the previous session.
As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.60, we find $3.00. Given the previous closing price of $0.80, this indicates a potential upside of 275.0 percent. XFOR stock price is now -28.22% away from the 50-day moving average and -43.82% away from the 200-day moving average. The market capitalization of the company currently stands at $123.55M.
Brokers who have rated the stock have averaged $3.51 as their price target over the next twelve months.
In other news, DiBiase Mary, Chief Operating Officer sold 2,642 shares of the company’s stock on Sep 08. The stock was sold for $3,300 at an average price of $1.25. Upon completion of the transaction, the Chief Operating Officer now directly owns 147,894 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 18, Director WYZGA MICHAEL S bought 25,000 shares of the business’s stock. A total of $29,875 was incurred on buying the stock at an average price of $1.20. This leaves the insider owning 76,667 shares of the company worth $57500.25. A total of 24.25% of the company’s stock is owned by insiders.
With an opening price of $0.7911 on Wednesday morning, X4 Pharmaceuticals Inc (NASDAQ: XFOR) set off the trading day. During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.65 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 0.55, a current ratio of 6.64, and a quick ratio of 6.64. The fifty day moving average price for XFOR is $1.0468 and a two-hundred day moving average price translates $1.3375 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc (NASDAQ: XFOR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.33, missing analysts’ expectations of -$0.16 by -0.17. This compares to -$0.60 EPS in the same period last year. The company reported revenue of $25.8 million for the quarter, compared to $20.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.45 percent.
X4 Pharmaceuticals Inc(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
